Aging Clocks May Reflect Disease Burden in Addition to Aging in Many Circumstances

When should we consider an age-related condition as being something distinct from aging? To what degree are aging clocks measuring burden of disease rather than burden of degenerative aging? These are questions that are difficult to provide generalized answers for without a consensus, very detailed definition of aging. It is possible to look at specific examples, however, in which it seems obvious and sensible to declare that the burden of that specific disease is distinct from what we might think of as aging, even given that the disease is age-related and arises from processes that we consider to cause aging. Infection leading to sepsis for example. Or later stages of cancer.

The authors of today's open access paper argue for aspects of cancer to be considered distinctly from aspects of aging. Cancer is clearly age-related and incidence of cancer is vastly greater in old age as the result of greater mutational damage, loss of immune surveillance, a more inflammatory environment, and other aspects of aging. Once cancer has developed, however, one might argue that a range of measures currently used to assess aging cease to reflect aging alone and start to reflect some combination of aging and the cancer.

Should we consider that having cancerous tissue inherently accelerates aging? In the not-all-that-useful definition of aging as an increased risk of mortality over time due to intrinsic causes, maybe so. But it doesn't seem entirely clear that it is otherwise helpful to think of tumors as inherently accelerating aging, in the context of any more detailed definition of aging as a process. On the other side of the coin, cancer does generate chronic inflammation and other metabolic disarray, and we all seem fairly comfortable in considering that these factors do accelerate aging regardless of cause. This might all be largely academic, if not for the existence of aging clocks, attempts to make use of aging clocks in the assessment of aging, and the pressing need for a consensus definition of aging at the detail level to better steer research and development.

Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer

PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. PhenoAge weights each component by a coefficient estimated to predict mortality in the U.S. general population (NHANES), and these coefficients were held fixed here, as in standard works on PhenoAge and cancer. Across four biologically distinct cancers, PhenoAge predicted outcome. Yet PhenoAge acceleration rose with tumor stage and added little to established clinicopathologic factors. Furthermore, its association with survival was carried by one or two routine components that differed by cancer and by endpoint, and this was reproduced when its population-derived weights were replaced by an unweighted +1 or -1. This pattern is not what a general measure of aging would show. A simpler explanation is that PhenoAge is sensitive to the systemic consequences of malignancy, which are already reflected in the routine blood tests it happens to contain.

Components of PhenoAge such as red blood cell distribution width, albumin, lymphocyte percentage and alkaline phosphatase reflect inflammation, nutritional status, immune function, and organ or tumor burden, all known to influence cancer outcomes. PhenoAge integrates these abnormalities, weights them according to a reference population, and expresses them as a "biological age." An association between accelerated PhenoAge and poor cancer outcomes can invite mechanistic conclusions about aging that PhenoAge itself does not establish. Our findings do not imply that biological aging is irrelevant to cancer; different clocks measure different things, and we tested only one. Rather, our findings suggest that studying aging in oncology will require measures whose signal can be distinguished from the inflammatory, nutritional, hematologic, and organ-specific consequences of the cancer and its treatment.

Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.